Thursday, January 26, 2023
News on Pathogens and Preparedness
Global Biodefense
  • Featured
  • COVID-19
  • Funding
  • Directory
  • Jobs
  • Events
  • Subscribe
No Result
View All Result
  • Featured
  • COVID-19
  • Funding
  • Directory
  • Jobs
  • Events
  • Subscribe
No Result
View All Result
Global Biodefense
No Result
View All Result
Home Pathogens

Submit Your Suggestions for the NIAID Tuberculosis Strategic Framework

by Global Biodefense Staff
July 5, 2018
Mycobacterium tuberculosis bacteria

Scanning electron micrograph of Mycobacterium tuberculosis bacteria, which cause TB. Credit: NIAID

The National Institute of Allergy and Infectious Diseases (NIAID) is developing a strategic framework to advance tuberculosis (TB) research and development for the next five years and beyond.

The NIAID TB Strategic Framework aims to progress areas of research opportunity vital to advancing understanding, prevention, and treatment of TB, and highlights research gaps critical to achieving the aspirational goal of ending TB.

The NIAID strategic framework is also aligned with NIAID’s ongoing efforts to intensify TB research and innovation in support of the U.S. Government Global Tuberculosis Strategy and the National Action Plan for Combating Multidrug-Resistant Tuberculosis, which share and complement the WHO commitment to reduce TB deaths by 95% and reduce TB incidence by 90% by 2035 through advancing TB research and innovation.

Highlighted areas of research opportunity include:

  • Host-pathogen interactions
  • Understand the epidemiology of TB (e.g., drug-resistant TB, impact of co-infections)
  • Discover novel biomarkers for diagnosis and prediction of treatment outcomes
  • Improve/develop accurate and rapid diagnostics (including point-of-care, non-sputum based, speciation, and drug-sensitivity) for all forms of TB, in all age groups
  • Discovery, design, development, and evaluation of novel vaccine candidates, antigen/adjuvant combinations, and delivery approaches
  • Enhance the breadth/durability of protective immune responses
  • Identify correlates of immune protection
  • Better characterize existing TB drug in situ pharmacokinetics/dynamics
  • Characterize and optimize existing animal models and develop novel animal models
  • Develop and standardize assays and reagents to assess vaccine efficacy

NIAID is seeking input from stakeholders throughout the scientific research community and the general public regarding the proposed framework.  All comments must be submitted electronically on the submission website.

Source: Grants.gov Notice Number: NOT-AI-18-043

Tags: Animal ModelsNIAIDPOC DiagnosticsRFITuberculosisVaccines

Related Posts

Influenza Proteins Tilt and Wave in ‘Breath-like’ Motions
Pathogens

Influenza Proteins Tilt and Wave in ‘Breath-like’ Motions

January 25, 2023
NIH Grant Awarded to Study Evolution of Lyme Disease Bacteria in Deer Ticks
Pathogens

NIH Grant Awarded to Study Evolution of Lyme Disease Bacteria in Deer Ticks

December 7, 2022
Bat Virus Receptor Studies Vital to Predict Spillover Risk
Pathogens

Bat Virus Receptor Studies Vital to Predict Spillover Risk

December 7, 2022
2022 Oral Rabies Vaccine Efforts Underway in Eastern United States
Pathogens

2022 Oral Rabies Vaccine Efforts Underway in Eastern United States

August 8, 2022
Load More

Latest News

Partner Therapeutics’ Novel Approach to Stratify Sepsis Patients Gains Backing From BARDA

Biopreparedness Research Virtual Environment (BRaVE) Initiative Backed by $105M DOE Funding

January 25, 2023
Influenza Proteins Tilt and Wave in ‘Breath-like’ Motions

Influenza Proteins Tilt and Wave in ‘Breath-like’ Motions

January 25, 2023
Biodefense Headlines – 24 January 2023

Biodefense Headlines – 24 January 2023

January 24, 2023
Biodefense Headlines – 17 January 2023

Biodefense Headlines – 17 January 2023

January 17, 2023

Subscribe

  • About
  • Contact
  • Privacy
  • Subscribe

© 2022 Stemar Media Group LLC

No Result
View All Result
  • Featured
  • COVID-19
  • Funding
  • Directory
  • Jobs
  • Events
  • Subscribe

© 2022 Stemar Media Group LLC